<p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）的股票在 HC Wainwright 发布给客户和投资者的研究报告中重申了 “买入” 评级，Benzinga 报道。他们目前对这家生物制药公司的股票目标价为 7.50 美元。HC Wainwright 的目标价意味着该股票当前价格有潜在的 343.79% 的上涨空间。</p>
<p>获取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
<ul>
<li>Akebia Therapeutics 因 FDA 批准贫血治疗而大幅上涨</li>
</ul>
<p>另外，StockNews.com 在 3 月 6 日的报告中将 Akebia Therapeutics 的评级从 “持有” 下调至 “卖出”。</p>
<p><strong>查看我们最新的 AKBA 股票分析</strong></p>
<h2>Akebia Therapeutics 股票下跌 12.4%</h2>
<p>AKBA 的股票在周五开盘价为 1.69 美元。Akebia Therapeutics 的 52 周低点为 0.80 美元，52 周高点为 2.48 美元。该公司的 50 日移动平均线为 2.01 美元，200 日移动平均线为 1.78 美元。该公司的市值为 3.6873 亿美元，市盈率为-7.35，贝塔值为 0.94。</p>
<p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）最近在 3 月 13 日发布了其财报。这家生物制药公司报告本季度每股收益为-0.10 美元，低于分析师一致预期的-0.05 美元，差距为 0.05 美元。该公司本季度的收入为 4650 万美元，而分析师预期为 3736 万美元。整体来看，股票研究分析师预计 Akebia Therapeutics 在本年度的每股收益为-0.3 美元。</p>
<h2>Akebia Therapeutics 的内部活动</h2>
<p>在相关消息中，高级副总裁 Steven Keith Burke 在 2 月 3 日的交易中出售了 50,506 股公司的股票。该股票以平均价格 2.10 美元出售，总交易额为 106,062.60 美元。出售后，这位高级副总裁现在直接持有 816,234 股公司股票，价值约为 1,714,091.40 美元。这笔交易代表其持股减少了 5.83%。该出售在向 SEC 的备案中披露，您可以通过此链接访问。此外，首席会计官 Richard C. Malabre 在 2 月 3 日的交易中出售了 30,202 股公司的股票。该股票以平均价格 2.10 美元出售，总价值为 63,424.20 美元。交易后，首席会计官现在直接持有 280,248 股公司股票，价值 588,520.80 美元。这笔交易代表其持股减少了 9.73%。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士已出售 280,579 股公司股票，价值 589,216 美元。目前 4.10% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。SRS Capital Advisors Inc.在第四季度购买了 Akebia Therapeutics 的新头寸，价值约为 26,000 美元。PDS Planning Inc 在第四季度收购了 Akebia Therapeutics 的股份，价值约为 28,000 美元。Mariner LLC 在第四季度购买了 Akebia Therapeutics 的新头寸，价值约为 28,000 美元。Cibc World Markets Corp 在第四季度购买了 Akebia Therapeutics 的新头寸，价值约为 37,000 美元。最后，Aquatic Capital Management LLC 在第四季度收购了 Akebia Therapeutics 的新股份，价值约为 47,000 美元。目前 33.92% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Akebia Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Akebia Therapeutics, Inc 是一家生物制药公司，专注于为肾脏疾病患者开发和商业化治疗方案。该公司的主要产品研发候选药物是 Vafseo（vadadustat），这是一种口服缺氧诱导因子脯氨酸羟化酶抑制剂，目前正在进行 III 期临床试验，治疗因慢性肾病（CKD）导致的贫血，适用于依赖透析和不依赖透析的患者。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Akebia Therapeutics</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>市场动能转变，但这三只股票经得起考验</li>
<li>工业产品股票投资</li>
<li>D-Wave Quantum 股票因 “量子霸权” 消息大涨</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>台湾半导体在美国的举动可能会改变芯片制造</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Akebia Therapeutics 吗？</h2>
<p>在考虑 Akebia Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Akebia Therapeutics 并不在名单上。</p>
<p>虽然 Akebia Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AKBA

<p>HC Wainwright 重申了对 Akebia Therapeutics（NASDAQ:AKBA）的 “买入” 评级，目标价格为 7.50 美元，较其当前价格 1.69 美元有 343.79% 的潜在上涨空间。该公司报告的季度每股亏损为 0.10 美元，低于预期，但收入为 4650 万美元，超出预期。近期注意到内部人士的股票出售和机构投资，机构投资者持有 33.92% 的股份。Akebia 专注于开发肾脏疾病的治疗方案，其主要产品正在进行针对慢性肾病引起的贫血的第三阶段临床试验</p>

<p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report)'s stock had its &#34;buy&#34; rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $7.50 target price on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 343.79% from the stock's current price.</p>
<div class="lb-trans"><p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）的股票在 HC Wainwright 发布给客户和投资者的研究报告中重申了 “买入” 评级，Benzinga 报道。他们目前对这家生物制药公司的股票目标价为 7.50 美元。HC Wainwright 的目标价意味着该股票当前价格有潜在的 343.79% 的上涨空间。</p>
</div><p>Get <strong>Akebia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Akebia Therapeutics Surges on FDA Approval for Anemia Treatment</li>
</ul>
<div class="lb-trans"><ul>
<li>Akebia Therapeutics 因 FDA 批准贫血治疗而大幅上涨</li>
</ul>
</div><p>Separately, StockNews.com cut Akebia Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Thursday, March 6th.</p>
<div class="lb-trans"><p>另外，StockNews.com 在 3 月 6 日的报告中将 Akebia Therapeutics 的评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on AKBA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 AKBA 股票分析</strong></p>
</div><h2>Akebia Therapeutics Stock Down 12.4 %</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 股票下跌 12.4%</h2>
</div><p>Shares of AKBA opened at $1.69 on Friday. Akebia Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $2.48. The company's fifty day moving average is $2.01 and its two-hundred day moving average is $1.78. The firm has a market cap of $368.73 million, a PE ratio of -7.35 and a beta of 0.94.</p>
<div class="lb-trans"><p>AKBA 的股票在周五开盘价为 1.69 美元。Akebia Therapeutics 的 52 周低点为 0.80 美元，52 周高点为 2.48 美元。该公司的 50 日移动平均线为 2.01 美元，200 日移动平均线为 1.78 美元。该公司的市值为 3.6873 亿美元，市盈率为-7.35，贝塔值为 0.94。</p>
</div><p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). The company had revenue of $46.50 million during the quarter, compared to analysts' expectations of $37.36 million. As a group, equities research analysts anticipate that Akebia Therapeutics will post -0.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）最近在 3 月 13 日发布了其财报。这家生物制药公司报告本季度每股收益为-0.10 美元，低于分析师一致预期的-0.05 美元，差距为 0.05 美元。该公司本季度的收入为 4650 万美元，而分析师预期为 3736 万美元。整体来看，股票研究分析师预计 Akebia Therapeutics 在本年度的每股收益为-0.3 美元。</p>
</div><h2>Insider Activity at Akebia Therapeutics</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 的内部活动</h2>
</div><p>In related news, SVP Steven Keith Burke sold 50,506 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $106,062.60. Following the sale, the senior vice president now directly owns 816,234 shares in the company, valued at approximately $1,714,091.40. This trade represents a 5.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Richard C. Malabre sold 30,202 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $63,424.20. Following the transaction, the chief accounting officer now directly owns 280,248 shares in the company, valued at $588,520.80. This trade represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 280,579 shares of company stock worth $589,216. 4.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，高级副总裁 Steven Keith Burke 在 2 月 3 日的交易中出售了 50,506 股公司的股票。该股票以平均价格 2.10 美元出售，总交易额为 106,062.60 美元。出售后，这位高级副总裁现在直接持有 816,234 股公司股票，价值约为 1,714,091.40 美元。这笔交易代表其持股减少了 5.83%。该出售在向 SEC 的备案中披露，您可以通过此链接访问。此外，首席会计官 Richard C. Malabre 在 2 月 3 日的交易中出售了 30,202 股公司的股票。该股票以平均价格 2.10 美元出售，总价值为 63,424.20 美元。交易后，首席会计官现在直接持有 280,248 股公司股票，价值 588,520.80 美元。这笔交易代表其持股减少了 9.73%。该出售的披露信息可以在这里找到。在过去 90 天内，内部人士已出售 280,579 股公司股票，价值 589,216 美元。目前 4.10% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. SRS Capital Advisors Inc. purchased a new position in Akebia Therapeutics in the 4th quarter valued at about $26,000. PDS Planning Inc acquired a new position in shares of Akebia Therapeutics in the fourth quarter worth about $28,000. Mariner LLC purchased a new position in Akebia Therapeutics in the fourth quarter valued at about $28,000. Cibc World Markets Corp purchased a new position in Akebia Therapeutics in the fourth quarter valued at about $37,000. Finally, Aquatic Capital Management LLC acquired a new stake in Akebia Therapeutics during the 4th quarter valued at approximately $47,000. 33.92% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。SRS Capital Advisors Inc.在第四季度购买了 Akebia Therapeutics 的新头寸，价值约为 26,000 美元。PDS Planning Inc 在第四季度收购了 Akebia Therapeutics 的股份，价值约为 28,000 美元。Mariner LLC 在第四季度购买了 Akebia Therapeutics 的新头寸，价值约为 28,000 美元。Cibc World Markets Corp 在第四季度购买了 Akebia Therapeutics 的新头寸，价值约为 37,000 美元。最后，Aquatic Capital Management LLC 在第四季度收购了 Akebia Therapeutics 的新股份，价值约为 47,000 美元。目前 33.92% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Akebia Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.</p>
<div class="lb-trans"><p>Akebia Therapeutics, Inc 是一家生物制药公司，专注于为肾脏疾病患者开发和商业化治疗方案。该公司的主要产品研发候选药物是 Vafseo（vadadustat），这是一种口服缺氧诱导因子脯氨酸羟化酶抑制剂，目前正在进行 III 期临床试验，治疗因慢性肾病（CKD）导致的贫血，适用于依赖透析和不依赖透析的患者。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Akebia Therapeutics</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>Market Momentum Shifts, But These 3 Stocks Are Built to Last</li>
<li>Industrial Products Stocks Investing</li>
<li>D-Wave Quantum Stock Jumps on &#34;Quantum Supremacy&#34; News</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>How Taiwan Semiconductor’s U.S. Move Could Shift Chipmaking</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Akebia Therapeutics</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>市场动能转变，但这三只股票经得起考验</li>
<li>工业产品股票投资</li>
<li>D-Wave Quantum 股票因 “量子霸权” 消息大涨</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>台湾半导体在美国的举动可能会改变芯片制造</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Akebia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Akebia Therapeutics 吗？</h2>
</div><p>Before you consider Akebia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Akebia Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Akebia Therapeutics 并不在名单上。</p>
</div><p>While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Akebia Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

药明康德（AKBA）在 HC Wainwright 的 “买入” 评级被再次确认